Dengue virus type 3 polyprotein (DENV-3 polyprotein)

Dengue virus type 3 (DENV-3) is one of the four distinct serotypes of the dengue virus, a mosquito-borne flavivirus that causes a wide spectrum of disease, from mild fever to life-threatening shock syndrome. The DENV-3 genome encodes a single polyprotein that is post-translationally cleaved into three structural proteins (Capsid, Pre-membrane, and Envelope) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). These proteins are the primary targets of the human adaptive immune system; the Envelope (E) protein is the major target for neutralizing antibodies, while non-structural proteins like NS3 and NS5 are critical for T-cell recognition and viral clearance (Pierson & Diamond, Nature Reviews Microbiology, 2020). NS1 is a key secreted glycoprotein used as a diagnostic biomarker and is also involved in immune evasion and vascular leak pathogenesis (WHO, 2023). A major challenge in targeting these proteins is antibody-dependent enhancement (ADE), where non-neutralizing or sub-neutralizing antibodies facilitate viral entry into Fc-receptor-bearing cells, potentially exacerbating the infection (Katzelnick et al., Science, 2017). Current therapeutic efforts focus on tetravalent vaccines, such as Dengvaxia and Qdenga, which incorporate DENV-3 antigens to elicit a balanced protective response against all four serotypes (The Lancet, 2020).

Other names

Dengue virus serotype 3 antigensDENV-3 structural and non-structural proteinsDENV3 proteomeDengue virus 3 polyprotein

Vaccines and immunotherapies targeting these proteins aim to induce neutralizing antibodies, primarily against the Envelope (E) protein to block viral attachment and fusion, and to prime T-cell mediated immunity against non-structural proteins (like NS3 and NS5) to identify and eliminate infected host cells.